ATC Group: L01XL04 Tisagenlecleucel

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01XL04 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01X Other antineoplastic agents
4 L01XL Antineoplastic cell and gene therapy
5 L01XL04

Active ingredients in L01XL04

Active Ingredient Description
Tisagenlecleucel

Tisagenlecleucel is an autologous, immunocellular cancer therapy which involves reprogramming a patient’s own T cells with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19 expressing cells.

Related product monographs

Title Information Source Document Type  
KYMRIAH Dispersion for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Canada (CA)

Croatia (HR)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Lithuania (LT)

Poland (PL)

Romania (RO)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.